Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5438 |
PROTAC CDK9 Degrader-1
|
CDK | Cell Cycle/Checkpoint |
PROTAC CDK9 Degrader-1 是一种选择性 CDK9 降解剂,是由Cereblon 配体和CDK 配体相连的PROTAC。 | |||
T74707 | PROTAC FLT3/CDK9 degrader-1 | ||
PROTACFLT3/CDK9 degrader-1 是一种有效的FLT3和CDK9双PROTAC 降解剂。PROTACFLT3/CDK9 degrader-1 诱导细胞凋亡 (Apoptosis) 并有效降解靶蛋白FLT3和 CDK9。PROTACFLT3/CDK9 degrader-1具有研究 FLT3-ITD 突变型 AML 的潜力。 | |||
T10743 |
CDK9-IN-11
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-11 是一种有效的CDK9抑制剂,可作为 PROTAC CDK9 Degrader-1 的配体。 | |||
T79904 |
PROTAC CDK9/CycT1 Degrader-2
|
CDK | Cell Cycle/Checkpoint |
PROTACCDK9/CycT1 Degrader-2 对CDK9表现出较高的抑制效能,具有一个IC50值为45 nM。 | |||
T74853 | PROTAC CDK9 degrader-7 | ||
PROTACCDK9 degrader-7 是一种特异性靶向CDK9的PROTAC。PROTACCDK9 degrader-7 通过蛋白酶体介导CDK9降解。 | |||
T17728 |
PROTAC CDK9 degrader-2
|
Others | Others |
PROTAC CDK9 degrader-2 (compounds 11c) is a potent and selective CDK9 degrader based on PROTAC, with an IC50 of 17 μM in MCF-7 cell lines. Natural product Wogonin binds ubiquitin E3 ligase cereblon (CRBN) via a linker to form PROTAC[1]. | |||
T78928 |
PROTAC CDK9 degrader-8
|
PROTACs | PROTAC |
PROTACCDK9degrader-8 (化合物21) 是具有0.01 μM IC50值的高效PROTAC CDK9降解剂,适用于癌症研究领域。 | |||
T12552 |
PROTAC CDK2/9 Degrader-1
|
CDK | Cell Cycle/Checkpoint |
PROTAC CDK2/9 Degrader-1 is a potent CDK2 and CDK9 dual degrader(DC50 of 62 nM and 33 nM). | |||
T74852 | PROTAC CDK9 degrader-6 | CDK | Cell Cycle/Checkpoint |
PROTACCDK9 degrader-6 是靶向CDK9的特异性PROTAC分子,能通过蛋白酶体介导的机制实现CDK9的降解。该化合物针对CDK942与CDK955异构体的DC50分别为0.03 μM和0.05 μM。 | |||
T74851 | PROTAC CDK9 degrader-5 | PROTACs | PROTAC |
PROTACCDK9 degrader-5为针对CDK9的特异性PROTAC分子,通过蛋白酶体途径介导CDK9的降解作用。针对CDK942和CDK955异构体,其DC50值分别为0.10 μM和0.14 μM。 | |||
T36744 |
CDK9 Antagonist-1
CDK9 Antagonist-1 |
||
CDK9 Antagonist-1 (compounds 11c) is a potent and selective CDK9 degrader based on PROTAC, with an IC50 of 17 μM in MCF-7 cell lines. Natural product Wogonin binds ubiquitin E3 ligase cereblon (CRBN) via a linker to form PROTAC[1]. CDK9|17 μM (IC50, MCF-7 cells) [1]. Bian J , et al. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bioorg Chem. 2018 Dec;81:373-381. | |||
T79704 |
CDK9-IN-28
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-28(化合物10)是一种高效CDK9抑制剂,可用作PROTAC合成中的靶蛋白配体,并在实体瘤中展现出显著的抗增殖能力。 | |||
T78837 |
CP-07
|
CDK | Cell Cycle/Checkpoint |
CP-07为高效的PROTAC CDK9选择性降解剂(DC50:43 nM),能显著抑制22RV1细胞增殖(IC50:62 nM)及集落形成,其作用机制为通过下调Mcl-1与c-Myc。此外,CP-07有效抑制22RV1异种移植肿瘤的生长,有望成为研究前列腺癌的重要化合物。 |